Between The Lines: Once Weekly Selinexor, Carfilzomib & Dexamethasone in Carfilzomib Non-Refractory Multiple Myeloma Patients

home / between-the-lines / between-the-lines-once-weekly-selinexor-carfilzomib-and-dexamethasone-in-carfilzomib-non

Dr. Joseph Mikhael and Dr. Hakan Kaya review key efficacy and safety data for the combination of Selinexor, Carfilzomib and Dexamethasone in R/R MM and discuss optimal dosing and adverse event management strategies for selinexor.